Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy

Experimental and Molecular Pathology

Volumn 92, Issue 2, 2012, Pages 217-221

  Palei, Ana C T ^a   Sandrim, Valeria C ^b   Amaral, Lorena M ^c   Machado, Jackeline S R ^c   Cavalli, Ricardo C ^c   Duarte, Geraldo ^c   Tanus Santos, Jose E ^c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Santa Casa of Belo Horizonte   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Genetic polymorphism; Gestational hypertension; Matrix metalloproteinase (MMP) 2; Preeclampsia

Indexed keywords

GELATINASE A; GENOMIC DNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MARKER GENE; MATERNAL HYPERTENSION; MMP 2 GENE; PATHOPHYSIOLOGY; PREECLAMPSIA; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; FEMALE; HAPLOTYPES; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MATRIX METALLOPROTEINASE 2; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; TISSUE INHIBITOR OF METALLOPROTEINASE-2; YOUNG ADULT;

EID: 84857273844     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.01.008     Document Type: Article

References (30)

1. Castro M.M., Rizzi E., Figueiredo-Lopes L., Fernandes K., Bendhack L.M., Pitol D.L., Gerlach R.F., Tanus-Santos J.E. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008, 198:320-331.
2. Castro M.M., Rizzi E., Prado C.M., Rossi M.A., Tanus-Santos J.E., Gerlach R.F. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biology 2010, 29:194-201.
3. Damsky C.H., Fitzgerald M.L., Fisher S.J. Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo. The Journal of Clinical Investigation 1992, 89:210-222.
4. Donnelly R., Collinson D.J., Manning G. Hypertension, matrix metalloproteinases and target organ damage. Journal of Hypertension 2003, 21:1627-1630.
5. Gremlich S., Nguyen D., Reymondin D., Hohlfeld P., Vial Y., Witkin S.S., Gerber S. Fetal MMP2/MMP9 polymorphisms and intrauterine growth restriction risk. Journal of Reproductive Immunology 2007, 74:143-151.
6. Isaka K., Usuda S., Ito H., Sagawa Y., Nakamura H., Nishi H., Suzuki Y., Li Y.F., Takayama M. Expression and activity of matrix metalloproteinase 2 and 9 in human trophoblasts. Placenta 2003, 24:53-64.
7. Kajantie E., Eriksson J.G., Osmond C., Thornburg K., Barker D.J. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke 2009, 40:1176-1180.
8. Lacchini R., Metzger I.F., Luizon M., Ishizawa M., Tanus-Santos J.E. Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA and Cell Biology 2011, 29:649-655.
9. Lacchini, R., Jacob-Ferreira, A.L., Luizon, M.R., Gasparini, S., Ferreira-Sae, M.C., Schreiber, R., Nadruz, W., Jr., Tanus-Santos, J.E., in press. Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. Journal of Human Hypertension doi:. doi:10.1038/jhh.2011.8.
10. Lambert E., Dasse E., Haye B., Petitfrere E. TIMPs as multifacial proteins. Critical Reviews in Oncology/Hematology 2004, 49:187-198.
11. Meekins J.W., Pijnenborg R., Hanssens M., McFadyen I.R., van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. British Journal of Obstetrics and Gynaecology 1994, 101:669-674.
12. Mizon-Gerard F., de Groote P., Lamblin N., Hermant X., Dallongeville J., Amouyel P., Bauters C., Helbecque N. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. European Heart Journal 2004, 25:688-693.
13. Montagnana M., Lippi G., Albiero A., Scevarolli S., Salvagno G.L., Franchi M., Guidi G.C. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. Journal of Clinical Laboratory Analysis 2009, 23:88-92.
14. Myers J., Mires G., Macleod M., Baker P. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension 2005, 45:258-263.
15. Myers J.E., Merchant S.J., Macleod M., Mires G.J., Baker P.N., Davidge S.T. MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. Hypertension in Pregnancy 2005, 24:103-115.
16. Narumiya H., Zhang Y., Fernandez-Patron C., Guilbert L.J., Davidge S.T. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertension in Pregnancy 2001, 20:185-194.
17. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. American Journal of Obstetrics and Gynecology 2000, 183:S1-S22.
18. Palei A.C., Sandrim V.C., Cavalli R.C., Tanus-Santos J.E. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clinical Biochemistry 2008, 41:875-880.
19. Price S.J., Greaves D.R., Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. Journal of Biological Chemistry 2001, 276:7549-7558.
20. Roberts J.M., Gammill H.S. Preeclampsia: recent insights. Hypertension 2005, 46:1243-1249.
21. Roy R., Zhang B., Moses M.A. Making the cut: protease-mediated regulation of angiogenesis. Experimental Cell Research 2006, 312:608-622.
22. Sankaralingam S., Arenas I.A., Lalu M.M., Davidge S.T. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Reviews in Molecular Medicine 2006, 8:1-20.
23. Shimonovitz S., Hurwitz A., Dushnik M., Anteby E., Geva-Eldar T., Yagel S. Developmental regulation of the expression of 72 and 92 kd type IV collagenases in human trophoblasts: a possible mechanism for control of trophoblast invasion. American Journal of Obstetrics and Gynecology 1994, 171:832-838.
24. Stephens M., Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. American Journal of Human Genetics 2005, 76:449-462.
25. Tayebjee M.H., Karalis I., Nadar S.K., Beevers D.G., MacFadyen R.J., Lip G.Y. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension. American Journal of Hypertension 2005, 18:325-329.
26. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circulation Research 2003, 92:827-839.
27. Vu T.H., Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes & Development 2000, 14:2123-2133.
28. WHO Make Every Mother and Children Count 2005, The World Health Organization Report, Genova.
29. Wilson B.J., Watson M.S., Prescott G.J., Sunderland S., Campbell D.M., Hannaford P., Smith W.C. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003, 326:845.
30. Yu C., Zhou Y., Miao X., Xiong P., Tan W., Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Research 2004, 64:7622-7628.